Priority Date: 01.06.16 (US 201662344297P)

NOVEL MUTATIONS IN ANAPLASTIC LYMPHOMA KINASE PREDICTING RESPONSE TO ALK INHIBITOR THERAPY IN LUNG CANCER PATIENTS

  • Application ID: EP17728807
  • Status: Request for examination was made

Applicants

Technology company logo small
Technology Company
Technology company logo small
Technology Company

Attorney

no operation time available
3 offices
Technology Company

Specialization

This EP application has the IPC class C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Roche Diagnostics GmbH is specialized in C12. Roche Diagnostics GmbH is specialised in C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 01.06.2016 - Priority Date (US 201662344297P)
  • 07.12.2017 - Publication A1 (WO2017207696)
  • 10.04.2019 - Publication A1 (EP3464625)

IPC Classification